 |
 |
|
|
|
| Formestane |
 |
| (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione |
 |
| 566-48-3 |
 |
Formestane belongs to a class of drugs known as aromatase inhibitors. It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. It is available as an intramuscular depot injection (Lentaron).
Formestane is often used to suppress estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a mild aromatase inhibitor.
Formestane has poor oral bioavailability and as such is no longer popular as many orally available aromatase inhibitors have been developed.
It is selective.
|
 |
CAS number 566-48-3
Formula C19H26O3
Mol. mass 302.408 g/mol
|
| Industrial field |
pharmaceutical |
|
|
 |
|
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
 |
|
|
|
